Recombinant Proteins Market by Product, Services, End-User, Function

List of Tables

[187 Pages Report] The Recombinant Proteins Market size was estimated at USD 5.05 billion in 2023 and expected to reach USD 5.80 billion in 2024, at a CAGR 14.51% to reach USD 13.04 billion by 2030.

The recombinant proteins are created by inserting a modified gene into an expression system such as bacteria, yeast, or mammalian cells, which then produce the desired protein with high purity and functionality. Recombinant proteins involve research, development, manufacturing, and commercialization of genetically engineered proteins derived from recombinant DNA technology. The prevalence of infectious and chronic diseases, increasing healthcare expenditure needed for new therapeutics and diagnostics, and increased R&D investments within biopharmaceutical companies are raising the need for high-quality recombinant proteins. The rapid advancements in genomics technologies and growing adoption of biologics over small-molecule drugs are resulting in increased adoption of recombinant proteins. However, the high cost of production and maintenance may adversely impact the use of recombinant DNA by the end-use industries. In addition, the emerging applications in animal reproduction and to enhance feed efficiency and significant investments in recombinant protein development are the factors expected to encourage the use of these proteins by the end-use sectors worldwide.

KEY MARKET STATISTICS
Base Year [2023]	USD 5.05 billion
Estimated Year [2024]	USD 5.80 billion
Forecast Year [2030]	USD 13.04 billion
CAGR (%)	14.51%

Product: Significant use of adhesion molecules & receptors for research purposes

Adhesion molecules and receptors are essential for cell-cell communication, migration, and immune response regulation. They are widely used in research to understand cancer, inflammation, and infection. Growth factors and chemokines regulate cellular growth, differentiation, and migration processes. They are vital for wound healing, tissue repair, and stem cell research applications. Immune response proteins are crucial components of the immune system that regulate infection defense mechanisms and inflammation control. Researchers use the immune response proteins to study autoimmune diseases and vaccine development. Kinase proteins are essential in cellular signal transduction pathways regulating cell division, survival, metabolism, and other biological processes. Kinase proteins possess significant potential as drug targets for cancer treatment and management of chronic inflammatory conditions. Membrane proteins are crucial for cell signaling, transport, and adhesion and have applications in drug discovery and development due to their involvement in numerous physiological processes. Recombinant metabolic enzymes are vital in biological pathways regulating cellular metabolism and energy production. They are used in drug discovery efforts targeting metabolic diseases, such as diabetes or obesity. Regulatory proteins control gene expression or cellular processes such as apoptosis and cell cycle progression. They are extensively used for cancer treatment and other diseases involving uncontrolled cell growth or differentiation. Structural proteins provide mechanical support to cells and tissues while maintaining structural integrity within organisms. They find applications in biomedical research related to tissue engineering or regenerative medicine.

Services: Expression services focus on high yields and compatibility with target protein characteristics

Recombinant protein cloning involves the insertion of a target gene into an appropriate expression vector, resulting in a recombinant DNA molecule that directs protein production in host cells. Need-based preferences for cloning services include high efficiency, specificity, and adaptability to different organisms. Expression refers to the process of translating a gene's information into a functional protein product. Several factors influence the choice of an expression system, such as productivity levels, compatibility with post-translational modifications (PTMs), and ease of scale-up for higher yields or purity levels required for downstream applications. Purification is essential to remove contaminants from the expressed protein and prepare it for downstream applications such as drug discovery, diagnostics, and research. Preferences for purification services include high selectivity, reproducibility, yield, and minimal sample loss. The demand for cloning services has increased due to advancements in molecular biology techniques, enabling the generation of multiple clones simultaneously. Expression services have evolved with improvements in host systems to accommodate diverse proteins with varying complexity levels. Purification services continue progressing with resin chemistry and instrumentation advances, allowing higher throughput and yields.

End-User: Extensive utilization of recombinant proteins in pharmaceutical and biopharmaceutical companies

Academic research institutes are the foundation for innovative and advanced research in recombinant protein technology. These institutes require high-quality, reliable, cost-effective recombinant proteins to study structural biology, functional studies, drug discovery, and diagnostics. Contract manufacturing organizations (CMOs) and contract research organizations (CROs) provide outsourced research and product development services to biopharmaceutical companies specializing in recombinant protein production, assay development, and preclinical testing. They value rapid turnaround times, competitive pricing structures, and customizable offerings tailored to their customer needs. Pharmaceutical biopharmaceutical companies require high-quality, GMP-compliant recombinant proteins for therapeutic and diagnostic product development. These end-user segments prioritize quality, reliability, and cost-effective solutions. Academic research institutes emphasize discovery-driven research application support; biotechnology companies value customization and scalability; CROs and CMOs prioritize turnaround time and customized offerings catering to diverse customers, while pharmaceutical and biopharmaceutical companies require robust manufacturing capabilities with strict regulatory compliance.

Function: Potential demand of recombinant proteins for drug discovery & development

Recombinant proteins are essential in diagnostics, facilitating detection and monitoring of various diseases. Enzyme-linked immunosorbent assays (ELISAs) and lateral flow immunoassays are common diagnostic techniques that utilize recombinant proteins as antigens or antibodies to detect specific biomarkers associated with specific diseases. Recombinant proteins play an indispensable role in drug discovery and production of biologics, vaccines, and cell and gene therapies and serve as potential therapeutic targets or drug candidates themselves. Additionally, they facilitate high throughput screening assays to identify lead compounds targeting specific disease pathways. Diagnostic applications primarily focus on sensitivity, specificity, rapidness, and cost-effectiveness. In contrast, drug discovery & development emphasizes recombinant proteins' purity, stability, scalability, and functional activity.

Regional Insights

The recombinant protein market is evolving in the Americas owing to the presence of well-established pharmaceutical and biotech companies with advanced research facilities and regulations that ensure high-quality products. Additionally, technological advancements, significant increases in funding for research and development (R&D), the rising prevalence of chronic conditions, and a surge in demand for personalized medicines are resulting in an increased need for recombinant protein in the Americas. The EMEA region represents a developing landscape for the recombinant proteins market owing to the stringent regulations implemented to use these proteins and the requirement for manufacturers to adhere to GMP standards. The recombinant proteins market is growing in the APAC region due to the prevalence of chronic diseases, increased research activities in cell biology, biochemistry, structural and biophysical studies, and the need for efficient biopharmaceuticals. Moreover, technological advancements and collaborations between biopharmaceutical companies and academic institutions are expected to increase the translation of laboratory innovations into commercially viable products and boost the adoption of recombinant proteins by the end-use sectors across the globe.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Recombinant Proteins Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Recombinant Proteins Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Recombinant Proteins Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC, Abnova Corporation, Agilent Technologies, Inc., Bhat Bio-tech India Private Limited, Bio-Rad Laboratories, Inc., Biogen Inc., BioLegend, Inc. by PerkinElmer, Inc., Biologics International Corp, BPS Bioscience, Inc., Bristol-Myers Squibb Company, Creative BioMart Inc., Croyez Bioscience Co., Ltd., Eli Lilly and Company, Enzo Life Sciences, Inc., Fortis Life Sciences LLC, GenScript Biotech Corporation, GeoVax Labs, Inc., Hzymes Biotech, Johnson & Johnson Services, Inc., Laurus Labs Limited, LenioBio GmbH, Lonza Group AG, Marin Biologic Laboratories, Inc., Merck KGaA, Meridian Bioscience, Inc. by SD Biosensor Inc., Miltenyi Biotec B.V. & Co. KG, Novartis AG, ProMab Biotechnologies, Inc., Proteintech Group, Inc., Proteos, Inc., R&D Systems, Inc. by Bio-Techne Corporation, Sanofi S.A., Sartorius AG, Selvita S.A., Sino Biological, Inc., SK bioscience, Takara Bio Inc., Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Recombinant Proteins Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Adhesion Molecules & Receptors
- Growth Factors & Chemokines
- Immune Response Proteins
- Kinase Proteins
- Membrane Proteins
- Recombinant Metabolic Enzymes
- Regulatory Proteins
- Structural Proteins

Services
- Cloning
- Expression
- Purification

End-User
- Academic Research Institutes
- Contract Research Organizations & Contract Manufacturing Organizations
- Pharmaceutical & Biopharmaceutical Companies

Function
- Diagnostics
- Drug Discovery & Development
  - Biologics
  - Cell & Gene Therapy
  - Vaccines
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Recombinant Proteins Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Recombinant Proteins Market?

3. What are the technology trends and regulatory frameworks in the Recombinant Proteins Market?

4. What is the market share of the leading vendors in the Recombinant Proteins Market?

5. Which modes and strategic moves are suitable for entering the Recombinant Proteins Market?

Product Code: MRR-501246437434

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising focus on personalized medicine & protein therapeutics in the consumers
  - 5.1.1.2. High prevalence of infectious & chronic diseases among geriatric population and children
  - 5.1.1.3. Surging inclination of demand toward biologics and biosimilars proteins
- 5.1.2. Restraints
  - 5.1.2.1. Concerns regarding time consumption coupled with high costs & maintenance of recombinant protein
- 5.1.3. Opportunities
  - 5.1.3.1. Increasing focus on biomarker discovery and surging investments recombinant protein development
  - 5.1.3.2. Growing potential for recombinant protein in animal reproduction, feed efficiency, and health
- 5.1.4. Challenges
  - 5.1.4.1. Availability of alternative products and several issues in production
5.2. Market Segmentation Analysis
- 5.2.1. Product: Significant use of adhesion molecules & receptors for research purposes
- 5.2.2. Services: Expression services focus on high yields and compatibility with target protein characteristics
- 5.2.3. End-User: Extensive utilization of recombinant proteins in pharmaceutical and biopharmaceutical companies
- 5.2.4. Function: Potential demand of recombinant proteins for drug discovery & development
5.3. Market Trend Analysis
- 5.3.1. Increase in research spending coupled with healthcare infrastructure across Americas
- 5.3.2. Prevalence of chronic diseases and significant investments in medical research in the APAC region
- 5.3.3. Expanding drug manufacturing facilities and regulatory guidelines for recombinant protein in the EMEA region.
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis

6. Recombinant Proteins Market, by Product

6.1. Introduction
6.2. Adhesion Molecules & Receptors
6.3. Growth Factors & Chemokines
6.4. Immune Response Proteins
6.5. Kinase Proteins
6.6. Membrane Proteins
6.7. Recombinant Metabolic Enzymes
6.8. Regulatory Proteins
6.9. Structural Proteins

7. Recombinant Proteins Market, by Services

7.1. Introduction
7.2. Cloning
7.3. Expression
7.4. Purification

8. Recombinant Proteins Market, by End-User

8.1. Introduction
8.2. Academic Research Institutes
8.3. Contract Research Organizations & Contract Manufacturing Organizations
8.4. Pharmaceutical & Biopharmaceutical Companies

9. Recombinant Proteins Market, by Function

9.1. Introduction
9.2. Diagnostics
9.3. Drug Discovery & Development

10. Americas Recombinant Proteins Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Recombinant Proteins Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Recombinant Proteins Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. iTolerance and Northway Biotech Form Manufacturing Pact for Fusion Protein
- 13.3.2. Biovian Invests Over EUR 50M in Manufacturing Facility in Finland
- 13.3.3. Fortis Life Sciences acquires International Point of Care
- 13.3.4. Curia Expands Cell Line Development Offering with CHOZN Platform
- 13.3.5. Future Fields raises USD 11.2 million to scale up fruit flies for recombinant protein production
- 13.3.6. Merck's Biodevelopment Centre Expansion, Martillac, France
- 13.3.7. Shenandoah Biotechnology Introduces Expanded Range of CTGrade Recombinant Proteins Manufactured Following cGMP Practices
- 13.3.8. Fujifilm to Acquire Shenandoah Biotechnology, Leading Manufacturer of Recombinant Proteins
- 13.3.9. Thermo Fisher Scientific Completes Acquisition of PeproTech, engaged in Recombinant Proteins

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio